Winhealth replaces Harbin Gloria in Cumberland licensing deal

U.S.-based Cumberland Pharmaceuticals Inc., has entered into an agreement with Winhealth Pharma Group to market Cumberland's Acetadote (acetylcysteine) and Caldolor (ibuprofen) in China. The deal comes after Harbin Gloria Pharmaceuticals failed to receive regulatory approval to market the drugs as part of a similar arrangement signed in 2012, as GBI reported.

Under the agreement, Winhealth will be responsible for regulatory affairs, marketing, distribution, and sales, while Cumberland will receive licensing payments, future royalties, and an upfront USD 2 million payment, with hopes of making USD 290 million in revenues during the first 10 years of the deal. Winhealth CEO Jack Wang commented that the company has experience working with other foreign companies such as Pfizer and Roche, and estimated that the drugs will be approved in two or three years thanks to China’s recent regulatory reforms.

Acetadote is a treatment for liver damage resulting from acetaminophen overdose, while Caldolor is used to treat pain and fever in the hospital setting.


Related news
Ecuador's National Agency for Health Regulation, Control and Surveillance (ARCSA) last week approved Pfizer’s pain reliever Lenivel-T (acetaminophen + tramadol), as GBI analysis reveals.
According to GBI analysis, Argentina's National Administration of Drugs, Foods and Medical Devices (ANMAT) recently issued a marketing approval for Pfizer’s flu therapy Ibupirac (ibuprofen + phenylephrine + chlorpheniramine).
U.S.-based major Pfizer (NYSE:PFE) is considering the “strategic options” open to its Consumer Healthcare business, incudling "full or partial separation” via “a spin-off, sale, or other transaction”, according to a statement.
U.S.-based multinational pharma Pfizer Inc., (NYSE: PFE) opened a new soft-capsule packaging plant for ibuprofen in Villa Soldati, Argentina.
The China Food and Drug Administration (CFDA) released its latest list of originator drugs that can be used as reference preparations for the purposes of generic drug quality and efficacy consistency evaluations.
Recent news
Argentina-based Laboratorios Bagó this week opened a new injectable drugs production facitlity in Buenos Aires.
Brazil’s health technology company WW8 last week launched its platform Athimos (, a medical communications and patient records system.
Brazil’s Ministry of Health has requested the Oswaldo Cruz Foundation (Fiocruz) to supply the Unified Health System (SUS) with immunosuppressant tacrolimus for kidney and liver transplant patients.
Cuba’s state-run biopharmaceutical group BioCubaFarma this week presented its products to Chile’s biotechnology and pharmaceutical industry.
Beijing-headquartered Contract Research Organization (CRO) Joinn Laboratories (China) Co., Ltd (603127.SH) has entered into an equity purchase agreement with U.S.-based pre-clinical CRO Biomedical Research Models Inc​.
The National Health Commission released its annual statistical round-up of China’s national health system during 2018.
Shanghai-based Allist Pharmaceuticals Inc., raised RMB 1.18 billion (USD 162 million) via a Series A financing round led by Shenzhen Shiyu Investment Management Co., Ltd​.
Analytics Snapshot